Gabapentin Enacarbil News and Research

RSS
XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort reports net loss of $19.1 million for fourth quarter 2013

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

Restless legs syndrome and insomnia: a possible explanation

Restless legs syndrome and insomnia: a possible explanation

Regnite to treat primary restless legs syndrome launched in Japan

Regnite to treat primary restless legs syndrome launched in Japan

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

XenoPort first quarter revenues increase to $10.4 million

XenoPort first quarter revenues increase to $10.4 million

GlaxoSmithKline, XenoPort receive FDA approval for Horizant to treat RLS

GlaxoSmithKline, XenoPort receive FDA approval for Horizant to treat RLS

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

XenoPort third quarter net loss decreases to $19.9 million

XenoPort third quarter net loss decreases to $19.9 million

FDA reviews GSK's response to Complete Response letter for Horizant

FDA reviews GSK's response to Complete Response letter for Horizant

GSK, XenoPort disappointed with GSK1838262/XP13512 phase 2b study for migraine headaches

GSK, XenoPort disappointed with GSK1838262/XP13512 phase 2b study for migraine headaches

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

European patent for XenoPort's investigational compound is valid

European patent for XenoPort's investigational compound is valid

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

FDA issues Complete Response Letter for Horizant in treatment of RLS

FDA issues Complete Response Letter for Horizant in treatment of RLS

Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval

Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval

FDA extends review date of New Drug Application for GSK1838262/XP13512

FDA extends review date of New Drug Application for GSK1838262/XP13512

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia